2023 Names & Themes To Watch
Insights - Below are a few names to watch, each divided into a different segment. Value: Atyr Pharma (LIFE)Atyr Pharma is currently enrolling for a pivotal Phase … Continue Reading
PremiumMust Read
Obesity & PD-1: History Doesn’t Repeat But It Rhymes
The early innings of the obesity landscape is starting to take shape, and it seems to be forming similar patterns...
Read NowModular Medical Submits 510(k) for Insulin Patch Pump
Modular Medical (MODD) announced the 510(k) submission of their MODD1 insulin pump to the FDA last week. On average, the FDA takes approximately...
PremiumLatest Posts
NK Sentiment and Impact on Affimed
Insights - Biotech (XBI) had a rocky 2022, seeing a near vertical drop in 1H 2022 and settling in around the low-$80 range in the second half … Continue Reading
Premium
Looking Back on 2022 Name Updates
Research - Ending a rather difficult 2022 with a few quick notes on names that were written about this year. Jounce’s $67M Asset SaleGilead acquired the remaining … Continue Reading
Premium
Notes from KOL on AFM13+NK ASH2022 Data
Insights - Yesterday, Slingshot Insights had a call with a lymphoma KOL on Affimed’s (AFMD) AFM13+NK data that was presented at ASH earlier in December. From an … Continue Reading
Premium
Affimed Scraps Mono AFM13 To Focus on Combinations
Insights - Affimed (AFMD) gave an update at the ASH conference this weekend for their AFM13 program in both monotherapy and combination w/ NK. The monotherapy data … Continue Reading
Premium
Astria Runs Ahead of Phase 1 Readout
Insights - Astria (ATXS) expects preliminary results from Phase 1a trial of STAR-0215 by year end 2022. The trial aims to establish the prolonged half-life and demonstrate inhibition … Continue Reading
Premium
Jounce Announces Yet Another Delay
Insights - Jounce Announces Yet Another DelayJounce will be reporting their Phase 2 proof of concept data for their LILRB2/ILT4 target in the 1H 2023. This timeline … Continue Reading
Premium